It was a consequential week for federal policy. Operation TrialBlazer is the kind of reform MassBio and our members have long pressed for to fight for American leadership in first-in-human trials. Leadership matters in moving the Massachusetts ecosystem forward and it meant a great deal to host Chairman Aaron Michlewitz and Chairman John Lawn in the Massachusetts Pavilion at BIO 2026 in San Diego to stand with MassBio and our industry.
FDA and HHS launch Operation TrialBlazer: HHS on June 22 unveiled a coordinated, department-wide clinical trials reform effort branded Operation TrialBlazer, the most concrete signal yet that the administration intends to fight for American leadership in first-in-human research. FDA is soliciting comments on a pilot program to shorten the time from drug identification to first-in-human Phase 1 trials and is clarifying regulatory expectations that it says could cut early trial timelines by six to twelve months. FDA also issued draft guidance clarifying that, in many cases, one high-quality late-stage trial with confirmatory evidence will generally suffice as substantial evidence of effectiveness. NIH, NCATS, NCI, ONC, and ARPA-H are advancing parallel efforts on AI, real-world data, and trial activation. This is an agency responding to exactly the feedback MassBio and our members have pressed for: clearer Phase 1 requirements, a faster pre-IND path, and resources aimed at the smaller companies that need them most. The direction is unmistakably right. The real test is follow-through and the durable, structural change our ecosystem needs will require Congress to act.
OMB’s grantmaking overhaul threatens the research engine behind the pipeline: We flagged this proposal a few weeks ago, but it’s worth revisiting because it sits in direct tension with Operation TrialBlazer. Published May 29, the proposal has researchers warning that it could destabilize the same research base that Operation TrialBlazer seeks to support, with one analysis cautioning the changes could threaten roughly 5,000 clinical trials. The proposal would replace the Uniform Guidance (2 CFR Part 200) with a binding, government-wide “Uniform Grants Regulation,” converting what had been agency-adopted guidance into a single regulatory lever that takes effect across NIH, NSF, and every other grantmaking agency at once. Its most consequential change would require senior political appointees to conduct a “pre-issuance review” of discretionary awards and explicitly bar them from simply deferring to peer reviewers. It would also let agencies terminate active, multi-year awards when priorities shift, mandate E-Verify for recipients, and make most publication and conference costs unallowable absent agency approval. OMB declined to impose the previously attempted 15 percent cap on indirect cost reimbursement, though the rule would give a competitive edge to applicants with lower negotiated rates. MassBio will submit comments before the July 13 deadline, focusing on how the termination and oversight provisions would inject real uncertainty into the federal funding landscape that the Massachusetts biotech ecosystem depends on.
BIO 2026 recap: China and AI dominate, FDA stability and pricing close behind: The BIO International Convention drew roughly 20,000 attendees to San Diego this week, and two themes dominated the conversations in and around the Convention Center: China and AI. On China, the prevailing conversation focused on competition or isolation. On AI, the open question was less whether it will reshape drug discovery than how to make its capabilities accessible to companies of every size. Running alongside both was a steady focus on FDA stability, keeping the agency “the gold standard of the world” while modernizing how it reviews and approves new medicines and on pricing, with multiple sessions examining how U.S. policy shifts are reshaping global launch strategies. The throughline was familiar and consistent with MassBio’s own message: the most effective answer to global competition is a stronger domestic innovation environment, not a retreat from it.
Looking ahead
The Senate is in recess next week and the House is in a short week due to the July 4 holiday, but we’re keeping a close eye on the House Small Business Committee, which holds a July 1 hearing on “250 Years of American Legacy: Small Businesses and the American Dream.”